Statements (14)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:administeredOrally |
true
|
| gptkbp:alsoKnownAs |
eltanexor
|
| gptkbp:clinicalTrialPhase |
Phase I/II
|
| gptkbp:developedBy |
Antengene Corporation
|
| https://www.w3.org/2000/01/rdf-schema#label |
ATG-016
|
| gptkbp:intendedUse |
gptkb:cancer
|
| gptkbp:mechanismOfAction |
selective inhibitor of nuclear export (SINE)
|
| gptkbp:relatedTo |
selinexor
|
| gptkbp:studiedIndication |
solid tumors
hematological malignancies |
| gptkbp:target |
exportin 1 (XPO1)
|
| gptkbp:bfsParent |
gptkb:Antengene
|
| gptkbp:bfsLayer |
7
|